247 related articles for article (PubMed ID: 10374543)
1. [OKT3 treatment of refractory renal allograft rejection].
Xu J; Ma J; Bai X
Zhonghua Wai Ke Za Zhi; 1997 Apr; 35(4):223-5. PubMed ID: 10374543
[TBL] [Abstract][Full Text] [Related]
2. [Orthoclone OKT3 in the treatment of intractable acute renal allograft rejection].
Yu LX
Zhonghua Wai Ke Za Zhi; 1993 Dec; 31(12):754-5. PubMed ID: 8033708
[TBL] [Abstract][Full Text] [Related]
3. OKT3 treatment for steroid-resistant acute rejection in kidney transplantation.
Sevmis S; Emiroglu R; Karakayali F; Yagmurdur MC; Dalgic A; Moray G; Haberal M
Transplant Proc; 2005 Sep; 37(7):3016-8. PubMed ID: 16213290
[TBL] [Abstract][Full Text] [Related]
4. Efficacy of OKT3 therapy for acute rejection in isolated lung transplantation.
Shennib H; Massard G; Reynaud M; Noirclerc M
J Heart Lung Transplant; 1994; 13(3):514-9. PubMed ID: 8061029
[TBL] [Abstract][Full Text] [Related]
5. Long-term efficacy of OKT3 for steroid-resistant acute rejection in renal transplant patients.
Kumano K; Irie A; Mashimo S; Endo T; Koshiba K
Transplant Proc; 1996 Jun; 28(3):1354-5. PubMed ID: 8658691
[No Abstract] [Full Text] [Related]
6. Immunologic monitoring of OKT3 induction therapy in cardiac allograft recipients.
Toyoda M; Galfayan K; Wachs K; Czer L; Jordan SC
Clin Transplant; 1995 Dec; 9(6):472-80. PubMed ID: 8645891
[TBL] [Abstract][Full Text] [Related]
7. OKT3 therapy in addition to tacrolimus is associated with improved long-term function in patients with steroid refractory renal allograft rejection.
Patschan D; Kribben A; Pietruck F; Lutz J; Binek M; Philipp T; Heemann U; Witzke O
Nephron Clin Pract; 2006; 103(3):c94-9. PubMed ID: 16534238
[TBL] [Abstract][Full Text] [Related]
8. OKT3 rescue therapy for 63 refractory rejections in 405 renal allografts.
Uchida K; Namii Y; Tominaga Y; Haba T; Tanaka H; Ichimori T; Uemura O; Morozumi K; Hayashi S; Yokoyama J; Takagi H
Transplant Proc; 1996 Jun; 28(3):1358-9. PubMed ID: 8658693
[No Abstract] [Full Text] [Related]
9. OKT3 treatment of cardiac allograft rejection.
Haverty TP; Sanders M; Sheahan M
J Heart Lung Transplant; 1993; 12(4):591-8. PubMed ID: 8369321
[TBL] [Abstract][Full Text] [Related]
10. Sparing of first dose effect of monovalent anti-CD3 antibody used in allograft rejection is associated with diminished release of pro-inflammatory cytokines.
Abbs IC; Clark M; Waldmann H; Chatenoud L; Koffman CG; Sacks SH
Ther Immunol; 1994 Dec; 1(6):325-31. PubMed ID: 7584508
[TBL] [Abstract][Full Text] [Related]
11. Two low-dose OKT3 induction regimens following renal transplantation--clinical experience at a single center.
Oh HK; Provenzano R; Tayeb J; Satmary N; Jones B
Clin Transplant; 1998 Aug; 12(4):343-7. PubMed ID: 9686329
[TBL] [Abstract][Full Text] [Related]
12. Delayed use of OKT3 for severe acute tubular necrosis in renal transplantation.
VanderWerf BA
Transplant Proc; 1996 Aug; 28(4):2115-6. PubMed ID: 8769172
[No Abstract] [Full Text] [Related]
13. Anti-CD3 and -CD4 monoclonal antibody in the treatment of steroid-resistant renal allograft rejection.
Wang XH; Xie T
Chin Med J (Engl); 1993 Nov; 106(11):821-4. PubMed ID: 8143493
[TBL] [Abstract][Full Text] [Related]
14. Phase I trial of a humanized, Fc receptor nonbinding OKT3 antibody, huOKT3gamma1(Ala-Ala) in the treatment of acute renal allograft rejection.
Woodle ES; Xu D; Zivin RA; Auger J; Charette J; O'Laughlin R; Peace D; Jollife LK; Haverty T; Bluestone JA; Thistlethwaite JR
Transplantation; 1999 Sep; 68(5):608-16. PubMed ID: 10507477
[TBL] [Abstract][Full Text] [Related]
15. [Neurologic complications induced by the treatment of the acute renal allograft rejection with the monoclonal antibody OKT3].
Fernández O; Romero F; Bravo M; Burgos D; Cabello M; González-Molina M
Neurologia; 1993 Oct; 8(8):277-80. PubMed ID: 8240843
[TBL] [Abstract][Full Text] [Related]
16. Treatment of cytomegalovirus infections with gancyclovir during OKT3 administration.
Haberal M; Velidedoğlu E; Arslan G; Bilgin N; Büyükpamukçu N; Karamehmetoğlu M
Transplant Proc; 1995 Oct; 27(5):2707. PubMed ID: 7482883
[No Abstract] [Full Text] [Related]
17. Influence of induction therapy on rejection and survival in heart transplantation.
Almenar L; García-Palomar C; Martínez-Dolz L; Chamorro C; Moro J; Zorio E; Arnau MA; Rueda J; Osa A; Cardo ML
Transplant Proc; 2005 Nov; 37(9):4024-7. PubMed ID: 16386616
[TBL] [Abstract][Full Text] [Related]
18. Efficacy of OKT3 as primary therapy for histologically confirmed acute renal allograft rejection.
Kamath S; Dean D; Peddi VR; Schroeder TJ; Alexander JW; Cavallo T; First MR
Transplantation; 1997 Nov; 64(10):1428-32. PubMed ID: 9392306
[TBL] [Abstract][Full Text] [Related]
19. Antimouse antibody response after OKT3 administration for steroid resistant rejection.
Kaiser BA; Palmer JA; Dunn SP; Mochon MA; Bartosh SM; Schulman SL; Polinsky MS; Baluarte HJ
Child Nephrol Urol; 1991; 11(4):190-2. PubMed ID: 1777898
[TBL] [Abstract][Full Text] [Related]
20. Increase of sTNF receptor levels in acute renal allograft rejection after treatment with OKT3.
Bemelman FJ; Jansen J; van der Poll T; van Deventer SJ; ten Berge RJ
Nephrol Dial Transplant; 1994; 9(12):1786-90. PubMed ID: 7708265
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]